

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Zoon *et al.*

Application No. 10/615,723

Filed: July 8, 2003

Confirmation No. 9429

For: INTERFERON ALPHA HYBRIDS

Examiner: Jegatheesan Seharaseyon

Art Unit: 1647

Attorney Reference No. 4239-64129-01

FILED VIA EFS

FILED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

LETTER TO EXAMINER: COMMENTS ON NOTICE OF ALLOWABILITY

Applicants thank Examiner Seharaseyon for the Notice of Allowability issued on April 3, 2007, and for his assistance throughout prosecution of this matter.

Further, Applicants thank the Examiner for indicating in the Notice that “[t]he instant invention is directed to hybrid interferon- α polypeptide of SEQ ID NO: 9, 11, 30, 32, 36, 38, 40 and 42 and the nucleotide of SEQ ID NO: 8, 10, 29, 31, 35, 37, or 41” (at page 4). Applicants understand that this statement is acknowledgement of the withdrawal of the requirement for restriction among these specific sequences, in view of the allowance of generic claim 1 (and the sequence defined generically therein). With regard to the same statement in the Notice, Applicants note on the record that the “instant invention” is in fact defined by the allowed claims, which are not limited to sequences in the listed SEQ ID NOs.

Examiner Seharaseyon is invited to telephone the undersigned if any questions remain.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Zoon *et al.***Application No.** 10/615,723**Filed:** July 8, 2003**Confirmation No.** 9429**FILED VIA EFS****For:** INTERFERON ALPHA HYBRIDS**Examiner:** Jegatheesan Seharaseyon**Art Unit:** 1647**Attorney Reference No.** 4239-64129-01

FILED VIA ELECTRONIC FILING SYSTEM

COMMISSIONER FOR PATENTS

TRANSMITTAL LETTER

Submitted herewith for filing in the above-referenced application are the following:

- In connection with issuance of a patent:
 - Form PTOL-85b
 - Advance order of 10 copies
- Letter to Examiner: *Comments on Notice of Allowability*

Applicants are paying \$1,730.00 herewith by EFS, for the following fees:

- Issue Fee (\$1,400.00)
- Publication Fee (\$300.00)
- Fee for Advance order copies (\$3.00 each - \$30.00)

The Director is hereby authorized to charge any additional fees that may be required in connection with issuance of a patent, or credit over-payment, to Account No. 02-4550.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630